A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

Angelini Farmacéutica9 enrolled

Overview

A 12-Month Observational Prospective Multicentre Cohort Study based on existing and newly collected data of schizophrenia patients followed-up for one year in secondary care settings (psychiatric services). Schizophrenia patients will be enrolled in a consecutive manner over a period of 6 month into two cohorts according to their prescribing switching treatment: to lurasidone (cohort A) and to another SGA (cohort B).

Study design A 12-Month observational prospective multicentre cohort study based on existing and newly collected data of schizophrenia patients followed-up for one year in secondary care settings (psychiatric services). Patients will be selected by the specialist when required to switch the SGA therapy for schizophrenia (index data). Schizophrenia patients will be enrolled in a consecutive manner over a period of 6 month into two cohorts: * Cohort A: patients who are prescribed to switch to lurasidone (lurasidone cohort) * Cohort B: patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort) The decision to switch the SGA treatment and prescribe the new treatment is done previously and independent from the decision to enter the patient into the study. Visit 0 will be performed when the investigator consider necessary to perform the treatment switch and patients give their informed consent to participate in the study. All patients will sign the Informed consent before starting the data collection. The duration of the study will be 12 months of follow-up after switching (visit 0): month 1 (visit 1), month 3 (visit 2), month 6 (visit 3) and month 12 (visit 4). Moreover, the clinical data of the patients recorded previous the index data will be collected in order to ensure that these patients were on an SGA monotherapy for a minimum of 3 months before switching to maximize potential weight gain and dysmetabolic problems that occurs early during the treatment. Preferably, patients have to be on treatment for a year or more before switching so that they have reached a weight plateau.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Schizophrenia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Female and male patients ≥ 18 years of age. 2. Patients with schizophrenia based on the Diagnostic of Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 3. Patients currently treated with oral SGA monotherapy for a minimum of 3 months that are prescribed\* to switch to another oral SGA medication. Patients will be included in a cohort depending on the switching treatment prescribed: * Cohort A: patients who are prescribed to switch to lurasidone (lurasidone cohort) * Cohort B: patients who are prescribed to switch to any other monotherapy SGA (other SGA cohort) \*Treatment switch and overlap period will be performed according to clinical practice and medical criteria. 4. Written informed consent prior to participation. Exclusion Criteria: 1. Patients with a known cardiovascular disease or suspected of having a heart disease. 2. Pregnant or breastfeeding women. 3. Patients diagnosed with at least one of the following: depression with psychotic symptoms, schizoaffective disorder, bipolar disorder or organic brain syndromes; Patients with active suicidal ideation or patients who have habitual and sustained consumption of alcohol and / or other toxic substances are also excluded. 4. Patients who had been treated with a long-acting within the last 6 months, or within last year in case of Trevicta®. 5. Concomitant treatments with antipsychotics for insomnia or anxiety (i.e., low doses of quetiapine, etumine, levomepromazine or similar). Concomitant treatment with sedative substances not considered antipsychotics (i.e., benzodiazepines or similar) when they are being taking regularly and at unchanged low doses are allowed. 6. Patients with history of seizures, stroke, neuroleptic malignant syndrome or epilepsy are excluded. 7. Current participation in any clinical trial. 8. Patients for whom further follow-up is not possible at the enrolling site.

Locations (10)

Hospital Regional de Málaga

Málaga, Andalusia, Spain

Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, Spain

Hospital Universitario Son Espases

Palma de Mallorca, Balearic Islands, Spain

Complejo Asistencial Universitario de León

Outcomes

Primary Outcomes

To analyze cardiometabolic profile changes based on metabolic syndrome factors changes from baseline to visit 2.

Body mass index, BMI (kg/m\^2)

Time frame: Month 3

To analyze cardiometabolic profile changes based on metabolic syndrome factors changes from baseline to visit 2.

Abdominal perimeter (cm)

Time frame: Month 3

To analyze cardiometabolic profile changes based on metabolic syndrome factors changes from baseline to visit 2.

Triglycerides(mg/dL)

Time frame: Month 3

To analyze cardiometabolic profile changes based on metabolic syndrome factors changes from baseline to visit 2.

High density lipoproteins-cholesterol (mg/dL)

Time frame: Month 3

To analyze cardiometabolic profile changes based on metabolic syndrome factors changes from baseline to visit 2.

systolic blood pressure (mm Hg)

Time frame: Month 3

To analyze cardiometabolic profile changes based on metabolic syndrome factors changes from baseline to visit 2.

Diastolic blood pressure (mm Hg)

Time frame: Month 3

To analyze cardiometabolic profile changes based on metabolic syndrome factors changes from baseline to visit 2.

fasting glucose levels (mg/dL)

Time frame: Month 3

Secondary Outcomes

To evaluate effectiveness from baseline.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

León, Castille and León, Spain

H. U. Salamanca

Salamanca, Castille and León, Spain

Complejo Asistencial de Zamora

Zamora, Castille and León, Spain

CHU Santiago

Santiago de Compostela, Galicia, Spain

Hospital Álvaro Cunqueiro

Vigo, Galicia, Spain

Hospital 12 de Octubre

Madrid, Spain

Hospital Universitario la Paz

Madrid, Spain

To evaluate effectiveness based on Brief Psychiatric Rating Scale scores from baseline. Smaller scores mean a better outcome. Min: 24; Max:168

Time frame: Month 3, month 6 and month 12

To evaluate effectiveness from baseline.

To evaluate effectiveness based on Clinical Global Impressions Ratings scores from baseline. Smaller scores mean a better outcome

Time frame: Month 3, month 6 and month 12

Analyze cardiometabolic profile changes based on metabolic syndrome factors

Body Mass Indez (kg/m\^2) changes from baseline to visit 1, 3 and 4.

Time frame: Month 3, month 6 and month 12

Analyze cardiometabolic profile changes based on metabolic syndrome factors

abdominal perimeter (cm) changes from baseline to visit 1, 3 and 4.

Time frame: Month 3, month 6 and month 12

Analyze cardiometabolic profile changes based on metabolic syndrome factors

Triglycerides (mg/dL) changes from baseline to visit 1, 3 and 4.

Time frame: Month 3, month 6 and month 12

Analyze cardiometabolic profile changes based on metabolic syndrome factors

High Densitity Lipoproteins - cholesterol (mg/dL) changes from baseline to visit 1, 3 and 4.

Time frame: Month 3, month 6 and month 12

Analyze cardiometabolic profile changes based on metabolic syndrome factors

Systolic Blood Preassure (mm Hg) changes from baseline to visit 1, 3 and 4.

Time frame: Month 3, month 6 and month 12

Analyze cardiometabolic profile changes based on metabolic syndrome factors

Diastolic Blood Preassure (mm Hg) changes from baseline to visit 1, 3 and 4.

Time frame: Month 3, month 6 and month 12

Analyze cardiometabolic profile changes based on metabolic syndrome factors

fasting glucose levels (mg/dL) changes from baseline to visit 1, 3 and 4.

Time frame: Month 3, month 6 and month 12

Analyze cardiometabolic profile based on other cardiovascular risk factors

To analyze cardiometabolic profile based on other cardiovascular risk factors (LDL-c (mg/dL), TC (mg/dL), HbA1c (%), creatinine (mg/dL), eGFR and prolactin (ng/ml) changes from baseline

Time frame: Month 1, month 3, month 6 and month 12

Analyze cardiometabolic profile based on other cardiovascular risk factors

Low Density Lipoproteins - cholesterol (mg/dL) changes from baseline

Time frame: Month 1, month 3, month 6 and month 12

Analyze cardiometabolic profile based on other cardiovascular risk factors

Total Cholesterol (mg/dL) changes from baseline

Time frame: Month 1, month 3, month 6 and month 12

Analyze cardiometabolic profile based on other cardiovascular risk factors

Hemoglobin A1c protein (%) changes from baseline

Time frame: Month 1, month 3, month 6 and month 12

Analyze cardiometabolic profile based on other cardiovascular risk factors

creatinine (mg/dL) changes from baseline

Time frame: Month 1, month 3, month 6 and month 12

Analyze cardiometabolic profile based on other cardiovascular risk factors

prolactine (ng/mL) changes from baseline

Time frame: Month 1, month 3, month 6 and month 12

QTc levels

To compare QTc levels from baseline to visit 4 (month 12)

Time frame: Month 12

Change in weight

To analyze the percentage of change in weight (kg) from baseline.

Time frame: Month 1, month 3, month 6 and month 12

Health-related quality of life (HRQoL) changes based on patient reported outcomes

To describe the health-related quality of life (HRQoL) changes based on patient reported outcomes from baseline.

Time frame: Month 3, month 6 and month 12

Health resources use

To analyze the health resources use during the study.

Time frame: Month 3, month 6 and month 12

Evaluate safety and tolerability

To evaluate safety and tolerability based on adverse events / adverse drug reactions (serious and non-serious) reported along the study

Time frame: through study completion, an average of 1 year

Reason for SGA discontinuation

To evaluate the reason for SGA discontinuation by antipsychotic therapy.

Time frame: through study completion, an average of 1 year